Turn Therapeutics Inc. (TTRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 1, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TTRX SEC filings page.
This page shows Turn Therapeutics Inc. (TTRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing-led balance-sheet expansion accompanied a much larger operating loss and a current-liquidity squeeze in FY2025.
Assets rose from$2.0M in FY2024 to$12.2M in FY2025, while operating cash flow remained negative. The financing inflow of$6.9M alongside that expansion indicates external capital, rather than internally generated cash, was the main funding mechanism.
Operating loss widened from
Current ratio fell from 1.6x to 0.9x, shifting from reported current-asset coverage to current liabilities exceeding current assets. Operating cash flow moved from
Financial Health Signals
Turn Therapeutics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Turn Therapeutics Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Turn Therapeutics Inc. reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Turn Therapeutics Inc. reported -$5.8M in net income in Q2 2026. This represents a decrease of 371.6% from the same quarter a year earlier. Against the prior quarter it is down 502.5%.
Turn Therapeutics Inc. earned -$0.20 per diluted share (EPS) in Q2 2026. This represents a decrease of 300.0% from the same quarter a year earlier. Against the prior quarter it is down 566.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Turn Therapeutics Inc. held $9.9M in cash against $6.1M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Turn Therapeutics Inc.'s ROE was -851.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 781.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 835.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Turn Therapeutics Inc. invested $475K in research and development in Q2 2026. This represents an increase of 657.9% from the same quarter a year earlier. Against the prior quarter it is up 334.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
TTRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $475K+657.9% | $109K+1081.9% | N/A | $159K+3.5% | $63K | $9K | N/A | $153K |
| SG&A Expenses | $1.2M-11.6% | $1.1M+202.5% | N/A | $1.8M+237.7% | $1.3M | $376K | N/A | $520K |
| Operating Income | -$1.6M-19.1% | -$1.2M-223.7% | N/A | -$1.9M-184.3% | -$1.4M | -$385K | N/A | -$673K |
| Interest Expense | $241K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.8M-371.6% | -$971K-195.5% | N/A | -$1.9M-185.7% | -$1.2M | -$329K | N/A | -$666K |
| EPS (Basic) | -$0.20-300.0% | -$0.03-200.0% | $0.01+150.0% | -$0.07-133.3% | -$0.05 | -$0.01 | -$0.02 | -$0.03 |
| EPS (Diluted) | -$0.20-300.0% | -$0.03-200.0% | $0.01+150.0% | -$0.07-133.3% | -$0.05 | -$0.01 | -$0.02 | -$0.03 |
| Diluted Shares (Avg) | 30M+8.3% | 29M+9.3% | N/A | 28M+5.0% | 27M | 27M | N/A | 27M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
TTRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $17.0M | $18.6M | $12.2M+493.6% | $4.3M | N/A | N/A | $2.0M | N/A |
| Current Assets | $10.4M | $11.5M | $5.2M+373.3% | $3.3M | N/A | N/A | $1.1M | N/A |
| Cash & Equivalents | $9.9M+211.9% | $11.0M+600.1% | $4.0M+708.3% | $514K+3.1% | $3.2M | $1.6M | $498K | $498K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $16.3M | $12.5M | $7.5M+235.8% | $3.8M | N/A | N/A | $2.2M | N/A |
| Current Liabilities | $8.8M | $5.1M | $6.0M+748.0% | $2.3M | N/A | N/A | $708K | N/A |
| Non-Current Liabilities | $7.5M | $7.4M | $1.5M-3.0% | $1.5M | N/A | N/A | $1.5M | N/A |
| Long-Term Debt | $6.1M | $5.9M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $687K-61.3% | $6.1M+647.2% | $4.7M+2741.4% | $504K+221.7% | $1.8M | $819K | -$177K | -$414K |
| Retained Earnings | -$29.2M | -$23.4M | -$22.4M-16.6% | -$22.7M | N/A | N/A | -$19.2M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
TTRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$923K-84.7% | -$1.6M-447.8% | -$1.2M-173.2% | -$589K | -$500K | -$298K | -$431K | N/A |
| Stock-Based Compensation | N/A | $281K+266.6% | N/A | N/A | N/A | $77K | N/A | N/A |
| Investing Cash Flow | -$6K | -$12K | -$31K-300.9% | -$90K | N/A | N/A | -$8K | N/A |
| Financing Cash Flow | $1-100.0% | $7.8M+680.1% | $3.2M+508.5% | $595K | $2.1M | $998K | $522K | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.87), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Turn Therapeutics Inc. Ranks
Frequently Asked Questions
Is Turn Therapeutics Inc. profitable?
No, Turn Therapeutics Inc. (TTRX) reported a net income of -$3.2M in fiscal year 2025.
What is Turn Therapeutics Inc.'s EBITDA?
Turn Therapeutics Inc. (TTRX) had EBITDA of -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Turn Therapeutics Inc.'s return on equity (ROE)?
Turn Therapeutics Inc. (TTRX) has a return on equity of -68.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Turn Therapeutics Inc.'s operating cash flow?
Turn Therapeutics Inc. (TTRX) recorded an outflow of $2.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Turn Therapeutics Inc.'s total assets?
Turn Therapeutics Inc. (TTRX) had $12.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Turn Therapeutics Inc. spend on research and development?
Turn Therapeutics Inc. (TTRX) invested $266K in research and development during fiscal year 2025.
What is Turn Therapeutics Inc.'s current ratio?
Turn Therapeutics Inc. (TTRX) had a current ratio of 0.87 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Turn Therapeutics Inc.'s debt-to-equity ratio?
Turn Therapeutics Inc. (TTRX) had a debt-to-equity ratio of 1.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Turn Therapeutics Inc.'s return on assets (ROA)?
Turn Therapeutics Inc. (TTRX) had a return on assets of -26.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Turn Therapeutics Inc.'s P/E ratio?
Turn Therapeutics Inc. (TTRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $404.2M as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Turn Therapeutics Inc.'s price-to-sales ratio?
Turn Therapeutics Inc. (TTRX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $404.2M as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Turn Therapeutics Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Turn Therapeutics Inc. (TTRX) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.6M over that year. Dividing the one by the other, the reported balance equals about 19 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Turn Therapeutics Inc.'s Piotroski F-Score?
Turn Therapeutics Inc. (TTRX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Turn Therapeutics Inc.'s earnings high quality?
Turn Therapeutics Inc. (TTRX) reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.